patent.fyi
Applications  /  US 2026/0355363
United States Patent Application Publication

US 2026/0355363 A1

Published
Nov 12, 2026
Filed
Feb 3, 2026
Earliest date on the face
Oct 29, 2019
Classification
A61K 51/088
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Radiolabeled antibody binds PSMA

What ifWhat if the imaging agent used a radiolabeled antibody that binds an extracellular region of PSMA?
Claim language“a compound according to Formula II”

The antibody binds PSMA exposed on the cell surface. A desferrioxamine group coupled to the antibody holds zirconium-89 for positron emission tomography.

1.2Ten-carbon polyether spacer

What ifWhat if S1 used a polyether spacer with a ten-carbon backbone?
Claim language“organic spacer group comprising 3-7 carbons”

Five oxyethylene units form a flexible spacer between the PSMA-binding head and the amino acid chain. The ether oxygens interact with water and keep the spacer hydrated.

1.3Aromatic linker replaces peptide

What ifWhat if a pyridine dicarboxamide linker connected S1 to the chelator-bearing portion?
Claim language“amino acid chain comprising 2-5 amino acids”

The two carboxyl groups of pyridine-2,5-dicarboxylic acid form amide bonds with amine handles on the adjoining segments. The aromatic ring fixes the relative positions of the two attachment points.

1.4Neutral side chains hydrate

What ifWhat if the amino acid chain used serine and asparagine side chains for hydration while remaining uncharged at physiological pH?
Claim language“one or more negatively charged amino acids”

A serine–asparagine–serine segment connects adjoining groups through amide bonds at both termini. The serine hydroxyls and asparagine side-chain amide form hydrogen bonds with water.

1.5Direct chelator attachment

What ifWhat if the amino acid chain attached directly to DOTA with no S2 spacer?
Claim language“organic spacer comprising 1-8 carbons”

A terminal amine on the amino acid chain forms an amide with one pendant carboxyl group of DOTA. The resulting DOTA monoamide binds a radiometal through its macrocyclic nitrogens and pendant oxygen donors.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Veterinary tissue receptor mapping

An ex vivo veterinary pathology workflow uses an indium-111-labeled PSMA-binding compound with the organic spacers, acidic peptide chain, and DOTA chelator. Adjacent frozen sections from a canine prostate specimen receive the radiotracer, with one section also receiving an excess of unlabeled PSMA ligand as a competition control. After washing, a phosphor imaging plate records retained radioactivity, and the difference between the paired images maps the displaceable signal.

Component substitution

Gallium labeling with a NOTA chelator

A bifunctional NOTA derivative replaces DOTA at the chelator end of the PSMA-binding scaffold. A pendant coupling group on the NOTA derivative forms an amide with a terminal amine on the second spacer while leaving the metal-binding donor groups available. The NOTA group coordinates gallium-68 in acetate buffer, and solid-phase extraction separates the labeled compound from free gallium before formulation for positron emission tomography.

Parameter or scale variation

Two terminal spacer lengths

Two compounds share a four-carbon first spacer, the same acidic peptide sequence, and a terminal DOTA group. The second spacer contains either two or six methylene units between its amide linkages, supplied by a protected beta-alanine or 7-aminoheptanoic acid building block, respectively. Each compound carries the same radionuclide, and a matched cell-binding assay measures the effect of spacer length at equal ligand concentration and incubation time.

Combination with existing systems

Uptake mapping with integrated PET and MRI

An integrated positron emission tomography and magnetic resonance system acquires uptake and anatomical images in the same patient position. A gallium-68-labeled PSMA agent retains the organic spacers, acidic peptide chain, and DOTA chelator. The scanner uses a magnetic resonance attenuation map for PET reconstruction and overlays the reconstructed uptake on a T2-weighted series to locate activity relative to the prostate capsule and adjacent structures.

Specimen imaging with a gamma camera

A shielded benchtop gamma camera images freshly excised tissue containing an indium-111-labeled PSMA agent with the same spacer, acidic peptide, and DOTA arrangement. An indexed specimen tray holds the specimen at a fixed distance from the collimator, and the camera collects counts in energy windows centered on 171 and 245 keV. The tray index aligns the count map with an optical photograph so the pathology team can select tissue blocks from areas of higher and lower uptake.

Automated or data-driven variant

Sensor controlled radiolabeling and formulation

A programmable radiochemistry module connects a gallium-68 supply, a vial containing the DOTA-bearing PSMA precursor, a heated reaction vessel, and a solid-phase extraction cartridge. The controller meters the radionuclide and buffered precursor into the vessel and uses a temperature sensor to start the programmed hold when the vessel reaches its setpoint. In-line radiation detectors track transfer to the cartridge and collection vial, and the controller records the temperature history and recovered activity for each batch.

Specific version of a part

Five-carbon alkylene spacer

S1 contains an unbranched segment of five methylene groups between its attachment points. Rotatable carbon–carbon bonds let the amino acid chain adopt different orientations relative to the PSMA-binding head.

Four-residue peptide segment

A consists of glycine, serine, glutamate, and glycine in that order, joined by three peptide bonds. Glycine occupies both terminal positions and presents the terminal groups for attachment to adjoining segments.

Two acidic side chains

A three-residue chain contains aspartate, glycine, and glutamate in that order. The aspartate and glutamate side-chain carboxyl groups are deprotonated at physiological pH and contribute two negative charges.

Hexamethylene spacer at S2

S2 uses a 1,6-diaminohexane residue with six methylene groups between the terminal nitrogens. Both nitrogens form amide bonds, linking the amino acid chain at one end and the chelator at the other.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2007/0106064 A1
Published
May 10, 2007
Filed
Oct 24, 2006
Class
A61K 38/12
Document BUS 8,648,176 B2
Published
Feb 11, 2014
Filed
Mar 1, 2010
Class
C07K 16/00
Claim 1
Document A
Document B
1.1a compound according to Formula II
1.2wherein S1 is an organic spacer group comprising 3-7 carbons
The present invention provides a convenient solid phase synthesis method for preparing peptide-spacer-lipid conjugates and provides various linkage groups (such as amide group) for conjugating peptide, spacer and lipid, wherein the spacer may comprise PEG.
A · US 2007/0106064 A1 · abstract
or a pharmaceutically acceptable salt thereof; wherein: each X is independently selected from carboxy, —C(═O)NHRd, —P(═O)(OH)(ORd), —S(═O)OH, —S(═O)2OH, —SH, —OH, —OC(═O)NHRd, —OC(═S)NHRd, —NHC(=0)NReRf, —NHC(═S)NReRf, —NReC(═O)NHRf, and —NReC(═S)NHRf; each L1 is, independently, C1-6 alkylene, C1-6 alkenylene, or C1-6 alkynylene, each of which is optionally substituted by 1, 2, or 3 groups independently selected from halogen, cyano, nitro, hydroxyl, C1-4 alkoxy, C1-4 haloalko
B · US 8,648,176 B2 · ¶ 89
1.3A is an amino acid chain comprising 2-5 amino acids
Engineered proteins: We tend to use the term “protein” to refer to longer or larger amino acid polymers and multi-chain or multi-unit proteinacious molecules, and we tend to use the term “polypeptide” to refer to shorter sequences or to a chain of amino acid residues within a larger molecule (e.g., within a fusion protein) or complex.
B · US 8,648,176 B2 · ¶ 42
1.4wherein the 2-5 amino acids comprise one or more negatively charged amino acids
The natural amino acids, having non-polar or hydrophobic side chains, include alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, and tryptophan; having acidic side chains, include aspartic acid, and glutamic acid; having basic side chains, include lysine, arginine, and histidine; and having uncharged hydrophilic side chains, include asparagine, glutamine, glycine, serine, threonine, tyrosine, and cysteine.
A · US 2007/0106064 A1 · ¶ 145
1.5S2 is optionally an organic spacer comprising 1-8 carbons
or a pharmaceutically acceptable salt thereof; wherein: each X is independently selected from carboxy, —C(═O)NHRd, —P(═O)(OH)(ORd), —S(═O)OH, —S(═O)2OH, —SH, —OH, —OC(═O)NHRd, —OC(═S)NHRd, —NHC(=0)NReRf, —NHC(═S)NReRf, —NReC(═O)NHRf, and —NReC(═S)NHRf; each L1 is, independently, C1-6 alkylene, C1-6 alkenylene, or C1-6 alkynylene, each of which is optionally substituted by 1, 2, or 3 groups independently selected from halogen, cyano, nitro, hydroxyl, C1-4 alkoxy, C1-4 haloalko
B · US 8,648,176 B2 · ¶ 89
1.6I1 comprises DOTA.

An empty cell means only that no passage was reproduced there.

Statements in these documents
Liposomes can provide several advantages for use as a drug delivery system for the reasons that they are safe to a biological system, have an excellent spherical bilayer for carrying ether hydrophilic or hydrophobic drugs, and can prevent drugs from degradation and diffusion.
A · US 2007/0106064 A1 · ¶ 4
However, when the end-group functionalized PEGs are conjugated to peptide ligands, a non-homogeneous conjugation may happen if there is more than one reaction group in the peptide ligands.
A · US 2007/0106064 A1 · ¶ 7
Chemotherapy is nonspecific and targets all rapidly dividing cells, resulting in undesirable side effects.
B · US 8,648,176 B2 · ¶ 4
The target can vary, and suitable targets include cancer antigens, small molecules (e.g., a pharmacologically active or inert compound such as a dye or other label), and proteins expressed by a eukaryotic cell, a prokaryotic cell, or a virus.
B · US 8,648,176 B2 · ¶ 5
Cite aspatent.fyi, US 2026/0355363 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355363/, SHA-256 74413b8d94d5fe580c711b22eb9107e1ff1fad0145d3116329c42f857e4be7d0
First published
Permanent addresshttps://patent.fyi/US20260355363/
Content fingerprint (SHA-256)74413b8d94d5fe580c711b22eb9107e1ff1fad0145d3116329c42f857e4be7d0
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi